| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Experimental Studies |
Department of Medicine, Lund University (B.A., H.L.), Malmö, Sweden; and Department of Medical Physiology, The Panum Institute (J.J.H.), Copenhagen University, Denmark
Address all correspondence and requests for reprints to: Bo Ahrén, Department of Medicine, Malmö University Hospital, S-205 02 Malmö Sweden.
Administration of the truncated glucagon-like peptide 1 (GLP-1) has been considered for treatment of noninsulin-dependent diabetes mellitus (NIDDM). We studied its antidiabetogenic mechanism by examining its influences on islet function and peripheral insulin sensitivity in six subjects (aged 56–74 yr) with well-controlled NIDDM. Islet function was evaluated with arginine stimulation at three plasma glucose levels (fasting, 14 mmol/L, and >28 mmol/L). GLP-1 (1.5 pmol/kg per min iv) increased serum insulin levels at fasting glucose (P = 0.028), at 14 mmol/L glucose (P = 0.028), and at 28 mmol/L glucose (P = 0.028). The acute insulin response (AIR) to 5 g iv arginine was increased by GLP-1 at 14 mmol/L glucose (P = 0.028), and the slopeAIR, i.e., the glucose potentiation of insulin secretion, was markedly increased by GLP-1 (P = 0.028). Plasma glucagon levels were reduced by GLP-1 (P = 0.028), and arginine-stimulated glucagon secretion (AGR) was inhibited by GLP-1 at 14 (P = 0.046) and 28 mmol/L glucose (P = 0.028). Glucose-induced inhibition of arginine-stimulated glucagon secretion (slopeAGR) was not significantly affected by GLP-1. In contrast, GLP-1 did not affect the low insulin sensitivity during a hyperinsulinemic, euglycemic clamp. Thus, GLP-1 improves islet dysfunction in diabetes, mainly by increasing the glucose-induced potentiation of insulin secretion. In contrast, the peptide does not seem to improve insulin resistance in NIDDM.
This article has been cited by other articles:
 |
|
 |
|
  J. E. Ayala, D. P. Bracy, F. D. James, B. M. Julien, D. H. Wasserman, and D. J. Drucker The Glucagon-Like Peptide-1 Receptor Regulates Endogenous Glucose Production and Muscle Glucose Uptake Independent of Its Incretin Action Endocrinology, March 1, 2009; 150(3): 1155 - 1164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Rickels, R. Mueller, J. F. Markmann, and A. Naji Effect of Glucagon-Like Peptide-1 on {beta}- and {alpha}-Cell Function in Isolated Islet and Whole Pancreas Transplant Recipients J. Clin. Endocrinol. Metab., January 1, 2009; 94(1): 181 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Edgerton, K. M.S. Johnson, D. W. Neal, M. Scott, C. H. Hobbs, X. Zhang, A. Duttaroy, and A. D. Cherrington Inhibition of Dipeptidyl Peptidase-4 by Vildagliptin During Glucagon-Like Peptide 1 Infusion Increases Liver Glucose Uptake in the Conscious Dog Diabetes, January 1, 2009; 58(1): 243 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Salehi, B. A. Aulinger, and D. A. D'Alessio Targeting {beta}-Cell Mass in Type 2 Diabetes: Promise and Limitations of New Drugs Based on Incretins Endocr. Rev., May 1, 2008; 29(3): 367 - 379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Azuma, Z. Radikova, J. Mancino, F. G. S. Toledo, E. Thomas, C. Kangani, C. Dalla Man, C. Cobelli, J. J. Holst, C. F. Deacon, et al. Measurements of Islet Function and Glucose Metabolism with the Dipeptidyl Peptidase 4 Inhibitor Vildagliptin in Patients with Type 2 Diabetes J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 459 - 464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Holst The Physiology of Glucagon-like Peptide 1 Physiol Rev, October 1, 2007; 87(4): 1409 - 1439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Thomaseth, A. Pavan, G. Pacini, and B. Ahren Glucagon-like peptide-1 accelerates the onset of insulin action on glucose disappearance in mice Am J Physiol Endocrinol Metab, June 1, 2007; 292(6): E1808 - E1814. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. L. Wajchenberg {beta}-Cell Failure in Diabetes and Preservation by Clinical Treatment Endocr. Rev., April 1, 2007; 28(2): 187 - 218. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-L. He, A. Horowitz, C. E. Watson, J. E. Foley, W. Sallas, and M. Ligueros-Saylan Vildagliptin Does Not Affect C-Peptide Clearance in Patients With Type 2 Diabetes J. Clin. Pharmacol., January 1, 2007; 47(1): 127 - 131. [Full Text] [PDF]
|
|
|
|
 |
|
 B. F. Burkey, X. Li, L. Bolognese, B. Balkan, M. Mone, M. Russell, T. E. Hughes, and P. R. Wang Acute and Chronic Effects of the Incretin Enhancer Vildagliptin in Insulin-Resistant Rats J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 688 - 695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Ahren, G. Pacini, J. E. Foley, and A. Schweizer Improved Meal-Related {beta}-Cell Function and Insulin Sensitivity by the Dipeptidyl Peptidase-IV Inhibitor Vildagliptin in Metformin-Treated Patients With Type 2 Diabetes Over 1Year Diabetes Care, August 1, 2005; 28(8): 1936 - 1940. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mari, W. M. Sallas, Y. L. He, C. Watson, M. Ligueros-Saylan, B. E. Dunning, C. F. Deacon, J. J. Holst, and J. E. Foley Vildagliptin, a Dipeptidyl Peptidase-IV Inhibitor, Improves Model-Assessed {beta}-Cell Function in Patients with Type 2 Diabetes J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4888 - 4894. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Ferrannini, A. Gastaldelli, Y. Miyazaki, M. Matsuda, A. Mari, and R. A. DeFronzo {beta}-Cell Function in Subjects Spanning the Range from Normal Glucose Tolerance to Overt Diabetes: A New Analysis J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 493 - 500. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Nikolaidis, A. Doverspike, T. Hentosz, L. Zourelias, Y.-T. Shen, D. Elahi, and R. P. Shannon Glucagon-Like Peptide-1 Limits Myocardial Stunning following Brief Coronary Occlusion and Reperfusion in Conscious Canines J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 303 - 308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Nystrom, M. K. Gutniak, Q. Zhang, F. Zhang, J. J. Holst, B. Ahren, and A. Sjoholm Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease Am J Physiol Endocrinol Metab, December 1, 2004; 287(6): E1209 - E1215. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. D'Alessio and T. P. Vahl Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes Am J Physiol Endocrinol Metab, June 1, 2004; 286(6): E882 - E890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Ahren, M. Landin-Olsson, P.-A. Jansson, M. Svensson, D. Holmes, and A. Schweizer Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2078 - 2084. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. B. Degn, C. B. Juhl, J. Sturis, G. Jakobsen, B. Brock, V. Chandramouli, J. Rungby, B. R. Landau, and O. Schmitz One Week's Treatment With the Long-Acting Glucagon-Like Peptide 1 Derivative Liraglutide (NN2211) Markedly Improves 24-h Glycemia and {alpha}- and {beta}-Cell Function and Reduces Endogenous Glucose Release in Patients with Type 2 Diabetes Diabetes, May 1, 2004; 53(5): 1187 - 1194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Prigeon, S. Quddusi, B. Paty, and D. A. D'Alessio Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect Am J Physiol Endocrinol Metab, October 1, 2003; 285(4): E701 - E707. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Quddusi, T. P. Vahl, K. Hanson, R. L. Prigeon, and D. A. D'Alessio Differential Effects of Acute and Extended Infusions of Glucagon-Like Peptide-1 on First- and Second-Phase Insulin Secretion in Diabetic and Nondiabetic Humans Diabetes Care, March 1, 2003; 26(3): 791 - 798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. S. Meneilly, C. H.S. McIntosh, R. A. Pederson, J. F. Habener, M. R.W. Ehlers, J. M. Egan, and D. Elahi Effect of Glucagon-Like Peptide 1 (7-36 Amide) on Insulin-Mediated Glucose Uptake in Patients With Type 1 Diabetes Diabetes Care, March 1, 2003; 26(3): 837 - 842. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. L. Kjems, J. J. Holst, A. Volund, and S. Madsbad The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion: Effects on {beta}-Cell Sensitivity in Type 2 and Nondiabetic Subjects Diabetes, February 1, 2003; 52(2): 380 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Pospisilik, S. G. Stafford, H.-U. Demuth, C. H.S. McIntosh, and R. A. Pederson Long-Term Treatment With Dipeptidyl Peptidase IV Inhibitor Improves Hepatic and Peripheral Insulin Sensitivity in the VDF Zucker Rat: A Euglycemic-Hyperinsulinemic Clamp Study Diabetes, September 1, 2002; 51(9): 2677 - 2683. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Egan, G. S. Meneilly, J. F. Habener, and D. Elahi Glucagon-Like Peptide-1 Augments Insulin-Mediated Glucose Uptake in the Obese State J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3768 - 3773. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Sudre, P. Broqua, R. B. White, D. Ashworth, D. M. Evans, R. Haigh, J.-L. Junien, and M. L. Aubert Chronic Inhibition of Circulating Dipeptidyl Peptidase IV by FE 999011 Delays the Occurrence of Diabetes in Male Zucker Diabetic Fatty Rats Diabetes, May 1, 2002; 51(5): 1461 - 1469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Meneilly, C. H.S. McIntosh, R. A. Pederson, J. F. Habener, R. Gingerich, J. M. Egan, and D. Elahi Glucagon-like Peptide-1 (7-37) Augments Insulin-Mediated Glucose Uptake in Elderly Patients With Diabetes J. Gerontol. A Biol. Sci. Med. Sci., November 1, 2001; 56(11): M681 - 685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Rask, T. Olsson, S. Soderberg, O. Johnson, J. Seckl, J. J. Holst, and B. Ahren Impaired Incretin Response After a Mixed Meal Is Associated With Insulin Resistance in Nondiabetic Men Diabetes Care, September 1, 2001; 24(9): 1640 - 1645. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Kieffer and J. Francis Habener The Glucagon-Like Peptides Endocr. Rev., December 1, 1999; 20(6): 876 - 913. [Abstract] [Full Text]
|
|
|
|
|
|
B. Ahren and G. Pacini Dose-related effects of GLP-1 on insulin secretion, insulin sensitivity, and glucose effectiveness in mice Am J Physiol Endocrinol Metab, December 1, 1999; 277(6): E996 - E1004. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. L. Brubaker, J. Schloos, and D. J. Drucker Regulation of Glucagon-Like Peptide-1 Synthesis and Secretion in the GLUTag Enteroendocrine Cell Line Endocrinology, October 1, 1998; 139(10): 4108 - 4114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Scrocchi and D. J. Drucker Effects of Aging and a High Fat Diet on Body Weight and Glucose Tolerance in Glucagon-Like Peptide-1 Receptor-/- Mice Endocrinology, July 1, 1998; 139(7): 3127 - 3132. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. M. Chapman, E. A. Goble, G. A. Wittert, J. E. Morley, and M. Horowitz Effect of intravenous glucose and euglycemic insulin infusions on short-term appetite and food intake Am J Physiol Regulatory Integrative Comp Physiol, March 1, 1998; 274(3): R596 - R603. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
